Abstract: Provided is ?3 desaturase having high enzymatic activity even at normal temperature. A polypeptide which consists of an amino acid sequence having an identity of 80% or more with the amino acid sequence represented by SEQ ID NO: 2 and has ?3 desaturation activity on C20 fatty acid, and a gene thereof.

Abstract: Provided is ?3 desaturase having high enzymatic activity even at normal temperature. A polypeptide which consists of an amino acid sequence having an identity of 80% or more with the amino acid sequence represented by SEQ ID NO: 2 and has ?3 desaturation activity on C20 fatty acid, and a gene thereof.

Abstract: Provided is an ?3 desaturase having a high enzymatic activity even at normal temperature. A polypeptide consisting of an amino acid sequence having an identity of 80% or more with the amino acid sequence represented by SEQ ID NO: 2 and having ?3 desaturation activity, and a gene therefor.

Abstract: The present invention provides a composition that exhibits favorable fat absorption inhibitory activity, is capable of being safely and easily taken continuously without side effects, and further is capable of preventing and/or improving conditions associated with excessive fat absorption such as obesity and hyperlipidemia. The present invention relates to a fat absorption inhibitory composition, which contains as an active ingredient a component that is collected as insoluble matter obtained by extracting wheat germ with water at 65° C. or lower and pH 5.0 or lower and treating the extract at 70° C. or higher and pH 6.0 or higher.

Abstract: A composition for effectively preventing or treating peptic ulcers not caused by Helicobacter pylori that does not cause any adverse reaction and thus is highly safe is provided. The present invention relates to a composition for preventing and/or treating peptic ulcers not caused by Helicobacter pylori, which comprises as an active ingredient a browning reaction product of a sugar and a protein.

Abstract: This invention relates to a medicament containing as an active ingredient, a novel propanolamine having a 1,4-benzodioxane ring or a pharmaceutically acceptable salt thereof: The present compound is represented by the above formula wherein R1-3 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxy group, a (C1–C6)alkyl group, a (C1–C6)alkoxy group, a (C1–C6)alkylsulfonamido group, or a phenyl group; R4-5 each represents a hydrogen atom or a (C1–C6)alkyl group; and A represents any of a benzene ring, a pyridine ring and a pyrimidine ring. This compound is useful as a prophylactic or therapeutic agent for diabetes, obesity, hyperlipemia, depression, a respiratory disease, or a gastrointestinal disease.

Abstract: This invention relates to a Helicobacter pylori adhesion inhibitor that is capable of eliminating Helicobacter pylori associated with the development of peptic ulcer from the stomach, a method for producing the same, and pharmaceutical compositions and foods for preventing or treating diseases associated with Helicobacter pylori comprising such Helicobacter pylori adhesion inhibitor. The inhibitor of the present invention has excellent activity of eradicating Helicobacter pylori and is highly safe. Accordingly, pharmaceutical compositions and foods comprising the same are highly useful for the prevention or treatment of the aforementioned diseases.

Abstract: Cyclic depsipeptides represented by the formula wherein: R is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15-carbon atoms; A, B, D, E and F independently each other are alanine, valine, leucine, isoleucine, phenylalanine, etc.; W and Z independently each other are aspartic acid, asparagine, glutamic acid or glutamine; and m and n independently each other is 0 or 1, or pharmacologically acceptable salts thereof. The present compounds are prepared according to a method conventionally used in peptide synthesis. The present compounds are useful as an agent for promoting the production of apolipoprotein E, a therapeutic agent for neurologic damages, a therapeutic agent for dementia, an agent for inhibiting the production of apolipoprotein B, an agent for promoting the production of apolipoprotein A1 or a therapeutic agent for hyperlipemia.

Abstract: This invention relates to a medicament containing as an active ingredient, a novel propanolamine having a 1,4-benzodioxane ring or a pharmaceutically acceptable salt thereof: 1

Abstract: A depsipeptide containing N-substituted glycine residue having the formula (1) or (2): (wherein R1 is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15 carbon atoms; R2 is a group of the formula —A—B—W—(D)m—(E)n, —A—B—W—(D)m—(E)n—F or —A—B—W—(D)m—(E)n—F—Z; R3 is a hydroxyl group, a lower alkoxy group, a benzyloxy group, or a group of the formula —Z, —Z—G or —Z—G—J; A, B, D, E, F, G and J independently are an N-substituted glycine residue or a residue of an amino acid selected from the group consisting of alanine, valine, leucine, serine, etc.; W and Z independently are a residue of an amino acid selected from the group consisting of an aspartic acid, a glutamic acid, etc.

Abstract: The present invention provides a new depsipeptide derivative having a piperazinone ring within the molecule which is represented by formula (1) wherein X1 represents N(R4)—CO, N(R5)—CH2, CH2—CO, CH2—CH2, CH═CH, CH2—CH(OH) or CH(OH)—CH(OH), R1 represents a C5-C20 alkyl group or a C5-C15 alkoxy C1-C4 alkyl group, R2-R5 represent a hydrogen atom or a C1-C6 alkyl group, and A represents a group of formula (2), (3) or (4) The depsipeptide derivative has a function of accelerating the production of apolipoprotein E and is useful as an agent for the treatment of neurologic injury, an agent for the treatment of dementia and an antihyperlipidemic agent.

Abstract: Depsipeptides represented by the formula (1): (wherein: R1 is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15 carbon atoms; R2 is —A—B, —A—B—W, —A—B—W—D or —A—B—W—D—E, R3 is a hydroxyl group, a lower alkoxy group, a benzyloxy group, —Z, —Z—G or —Z—G—J, the above A, B, D, E, G and J independently each other are a residue of an amino acid selected from alanine, valine, leucine, isoleucine, serine, threonine, lysine, hydroxylysine, arginine, cysteine, methionine, phenylalanine, tyrosine, aspartic acid, asparagine, glutamic acid, glutamine and the like or an N—(C1-C4) alkyl derivative of these amino acid residues; the above W and Z independently each other are a residue of an amino acid selected from aspartic acid, asparagine, glutamic acid, glutamine, alanine, serine or lysine) or pharmacologically acceptable

Abstract: A depsipeptide containing a non-natural amino acid(s) having the formula (1) wherein R1 represents a C5-C20 alkyl group and others; R2 represents —O—CO—CH(R5)—X—CH(R6)—NH— (wherein X represents N(R7)—CO, CH2—CO, CH2—CH2 and others, R5, R6, and R7 represent a hydrogen atom or a C1-C6 alkyl group); R3 represents and wherein the remaining substituent variables are as defined herein. The above depsipeptides have a promoting activity on the production of apolipoprotein E, and are useful as a therapeutic agent for neurologic damages, especially dementia, and hyperlipemia.

Abstract: The present invention provides a bicyclic depsipeptide having the formula (1) wherein: R is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15 carbon atoms; A, D, E and J independently are a residue of an amino acid selected from the group of alanine, valine, leucine, etc.; B and F are the same or different and a residue of an amino acid selected from the group consisting of cysteine, aspartic acid, glutamic acid, lysine, hydroxylysine and serine; G is a disulfide bond, an amido bond or an ester bond; W is a residue of an amino acid selected from the group consisting of aspartic acid and glutamic acid; Z is a residue of an amino acid selected from the group consisting of aspartic acid, asparagine, glutamic acid and glutamine; l, m, n, p and q independently are 0 or 1; or a pharmacologically acceptable salt thereof.

Abstract: A depsipeptide containing N-substituted glycine residue having the formula (1) or (2): ##STR1## (wherein R.sub.1 is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15 carbon atoms; R.sub.2 is a group of the formula --A--B--W--(D).sub.m --(E).sub.n, --A--B--W--(D).sub.m --(E).sub.n --F or --A--B--W--(D).sub.m --(E).sub.n --F--Z; R.sub.3 is a hydroxyl group, a lower alkoxy group, a benzyloxy group, or a group of the formula --Z, --Z--G or --Z--G--J; A, B, D, E, F, G and J independently are an N-substituted glycine residue or a residue of an amino acid selected from the group consisting of alanine, valine, leucine, serine, etc.; W and Z independently are a residue of an amino acid selected from the group consisting of an aspartic acid, a glutamic acid, etc.; at least one of A, B, D, E, F, G and J is an N-substituted glycine residue) or a pharmacologically acceptable salt thereof.

Abstract: A cyclic depsipeptide having the general formula (I) ##STR1## (wherein n is an integer of 5-15) or a pharmacologically acceptable salt thereof. The present compound can be prepared by cultivation of a cyclic depsipeptide-producing microorganism belonging to the genus of Bacillus. The present compounds are useful as a therapeutic agent for hyperlipemia, an agent for inhibiting the secretion of lipids or an agent for inhibiting the production of apolipoprotein B.

Abstract: Urea derivatives of formula (I) ##STR1## wherein the valuable groups are as defined in the specification, which possess both an ACAT inhibitory activity and an antioxidative activity. Those derivatives are useful in the prophylaxis and treatment of hypercholesterolemia and atherosclerosis.

Abstract: Urea derivatives of formula (1) ##STR1## wherein the valuable groups are as defined in the specification, which possess both an ACAT inhibitory activity and an antioxidative activity. Those derivatives are useful in the prophylaxis and treatment of hypercholesterolemia and atherosclerosis.

Abstract: Mycotrienin-related compounds called the T-23-X, -XI, -XII, -XIII and -XIV. These compounds are isolated and characterized by structural formula and other identifying data. They are useful in the treatment of tumors.

Abstract: Mycotrienin-related compounds called the T-23-VIII and T-23-IX substances. These substances are isolated and characterized by structural formula and other identifying data. These substances are useful in the treatment of tumors.